Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > A Catalyst New Event

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Nov 22, 2022 3:26pm

165 Views

Post# 35119691

RE:RE:RE:RE:RE:A Catalyst New Event

@carbonW - We should be very clear about ONCY trials as there are a number of them and one can get confused. The pancreatic trial you refer to with Keytruda NCT03723915 was Terminated.

To my knowledge( and I am always happy to be corrected) the only ongoing trial with Keytruda is AMBUSH. It started recruiting 11/15/22 and is for Relapsed or Refractory Multiple Myeloma. I think AMBUSH was a surprise to most; an ambush if you will. Said trial does strike me as very encouraging. Cheers

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 22, 2024)